TapImmune Inc. (NASDAQ:MRKR) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 4,977,900 shares, an increase of 5.5% from the July 31st total of 4,716,300 shares. Currently, 56.5% of the shares of the company are short sold. Based on an average trading volume of 704,500 shares, the days-to-cover ratio is currently 7.1 days.

Shares of MRKR stock traded up $0.09 during trading on Friday, reaching $5.90. 707,058 shares of the company’s stock traded hands, compared to its average volume of 309,553. The company has a market capitalization of $265.35 million, a P/E ratio of -3.53 and a beta of 0.28. The company has a current ratio of 16.85, a quick ratio of 16.85 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average is $5.05 and its 200 day moving average is $5.96. TapImmune has a 1 year low of $3.97 and a 1 year high of $10.60.

TapImmune (NASDAQ:MRKR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. As a group, sell-side analysts predict that TapImmune will post -0.51 earnings per share for the current fiscal year.

In related news, insider Peter L. Hoang bought 10,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average cost of $4.62 per share, for a total transaction of $46,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.70% of the stock is owned by insiders.

A number of analysts recently commented on the stock. Zacks Investment Research cut shares of TapImmune from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. ValuEngine cut shares of TapImmune from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Oppenheimer assumed coverage on shares of TapImmune in a research note on Wednesday, July 3rd. They set an “outperform” rating and a $15.00 price target on the stock. Nomura restated a “buy” rating and set a $16.00 price target on shares of TapImmune in a research note on Tuesday, August 13th. Finally, Roth Capital assumed coverage on shares of TapImmune in a research note on Thursday, May 30th. They set a “buy” rating and a $10.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TapImmune has an average rating of “Buy” and a consensus target price of $10.21.

TapImmune Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Recommended Story: How are dividend achievers different from dividend aristocrats?

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.